ClinicalTrials.gg
CompletedNCT04879550Updated May 24, 2022

Prospective Investigation of Antithrombin III Deficiency in Adult Patients With ECMO

An observational study in Antithrombin III Deficiency and Extracorporeal Membrane Oxygenation Complication, sponsored by Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital. Completed at 1 site in Turkey. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-24.

Sponsored by Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Study summary

There are publications showing a decrease in Antithrombin III levels of continuous flow and routine heparin therapy in adult patients undergoing Extracorporeal Membrane Oxygenation (ECMO) however, there is not enough data. One of the multifactorial causes affecting bleeding / thrombosis complications and ACT levels may be acquired Antithrombin III deficiency.

The Antithrombin III activity test results from the patients to be included in the study during the study will be recorded immediately after ECMO run, at the 24th hour before the heparin infusion start and at the 48th, 72nd and 96th hours following the follow-up. The results will be analyzed to figure out a relationship between decreasing Antithrombin 3 values and thrombotic events.

Read the detailed description

ECMO is applied in patients with acute severe heart or lung failure. The treatment protocol of patients undergoing ECMO is carefully arranged against the risk of bleeding / thrombosis.

According to the general protocol, heparin infusion therapy is started at the 24th hour after ECMO application. The risk of bleeding / thrombosis is avoided by adjusting the heparin infusion dose with Activated Clotting Time (ACT) control. However, over time, thrombocytopenia and fluctuations in ACT level are observed in patients. It may be necessary to increase the dose of heparin given during the prolonged period. One of the multifactorial causes affecting bleeding / thrombosis complications and ACT levels may be acquired Antithrombin III deficiency. There are publications reporting a decrease in Antithrombin III levels of continuous flow and routine heparin therapy in adult patients undergoing ECMO; however, there is not enough data.

The Antithrombin III activity test results from the patients to be included in the study during the study will be recorded immediately after ECMO run, at the 24th hour before the heparin infusion start and at the 48th, 72nd and 96th hours following the follow-up. The results will be analyzed to figure out a relationship between decreasing Antithrombin 3 values and thrombotic events.

02

Conditions studied

  • Antithrombin III Deficiency
  • Extracorporeal Membrane Oxygenation Complication

Keywords

  • Antithrombin III, ECMO
03

In context

Lead sponsor

Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All patients over the age of 18 who underwent ECMO in our hospital are our study population.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Being over the age of 18
  • Patients with ECMO run for 3 days or more (to be able to determine at least 3 antithrombin 3 levels)

Exclusion criteria

Exclusion Criteria:

  • Patients with ECMO run less than 3 days
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • thrombotic event developing / not

    Group I: Patients with no bleeding/thrombosis complications Group II: Patients with Thrombotic and/or thromboembolic complications Group III: Patients with bleeding complications

    Diagnostic Test: Antithrombin III

Interventions

  • Diagnostic testAntithrombin III

    Antithrombin III deficiency causes thrombosis. Is thrombosis in ECMO patients related to Antithrombin III deficiency? Groups with and without thrombosis will be separated and whether it is related to Antithrombin III deficiency will be evaluated.

06

What researchers measure

Primary outcomes

  1. Antithrombin 3 activity level

    Antithrombin 3 activity test levels will be checked in the first 5 days after ecmo application.

    Time frame: 5 days

Secondary outcomes

  1. Thrombosis and Bleeding Events

    Thrombotic or bleeding complications occurring during ECMO run

    Time frame: 1 week

07

Study locations

1 site
  • Istanbul Dr.Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital
    Istanbul, 34668, Turkey
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Jan 2022, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2021
First posted
May 10, 2021
StartActual
Jan 1, 2020
Primary completionActual
Jan 1, 2022
CompletionActual
Mar 1, 2022
Last update
May 24, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04879550
Lead sponsor
Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital
Responsible party
Arif Yasin Çakmak (Principal Investigator, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital) — Principal investigator
First posted
May 10, 2021
Start date
Jan 1, 2020
Primary completion
Jan 1, 2022
Completion
Mar 1, 2022
Last update
May 24, 2022

Study contacts

Serap AKA
study director · Cardiovascular Surgeon

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion